Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has patented cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of cancer.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has disclosed pyrimidines or pyridines acting as adenosine receptor antagonists reported to be useful for the treatment of cancer.
Accutar Biotechnology Inc. has identified sulfonamides acting as epidermal growth factor receptor (EGFR) (mutant) inhibitors reported to be useful for the treatment of cancer.
There is still a percentage of patients with multiple myeloma (MM) who do not respond to initial therapy, and they are considered as refractory MM patients. There is a need for novel biomarkers of treatment response in refractory MM.
Biocytogen Pharmaceuticals Co. Ltd. has raised HK$471.1 million (US$60 million) in net proceeds through an initial public offering on the Hong Kong Stock Exchange Sept. 1. It plans to use about three-quarters of the proceeds to advance clinical trials of two of its core anticancer candidates, YH-003 and YH-001. Company shares (HKEX:2315), initially offered at HK$25.22 each, closed at HK$26 on their first trading day.
Sinocelltech Group Ltd. has received marketing approval for its recombinant chimeric anti-CD20 monoclonal antibody, ripertamab (SCT-400), from China’s NMPA to treat patients with CD20-positive diffuse large B-cell lymphoma. The country’s first homegrown anti-CD20 therapy, ripertamab has been shown to have similar efficacy to global blockbuster rituximab but with a superior safety profile.
Laverock Therapeutics Ltd. (formerly Skylark Therapeutics) recently completed a seed funding round to support its development of a unique gene silencing platform for the creation of programmable, allogeneic cell therapies.
Eikonizo Therapeutics Inc. has identified histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer and neurological disorders, among others.
RSS
